Sudo Biosciences Raises Additional $30M in Series B; Brought Total Round to $147M


Sudo Biosciences, a Carmel, IN-based biopharmaceutical company committed to designing and developing precision TYK2 (tyrosine kinase 2) inhibitors, raised additional $30M in Series B funding.

The round, which brought the total amount to $147M, was led by Enavate Sciences and TPG, with participation from Sanofi Ventures, Frazier Life Sciences, Surveyor Capital (a Citadel company), Monograph Capital, Eventide Asset Management, Velosity Capital and new investors DDF, Leaps by Bayer, and UPMC Enterprises. With this second Series B round close, Sudo has raised a total of $188M since its founding in 2020.

The company intends to use the funds to advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions.

Led by Scott Byrd, Chief Executive Officer, Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel medicines to transform patients’ lives. Its programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. The company’s pipeline of next generation TYK2 inhibitors includes a potential brain-penetrant candidate for the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a potential topical candidate for immune-mediated dermatologic diseases. Both candidates are anticipated to enter clinical trials in 2024. The company has operations across the US and UK.